UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 or 15(d)

of the Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): ~~September 12~~November 6, 2025

LB Pharmaceuticals Inc

(Exact name of registrant as specified in its charter)

Delaware	001-42831	81-1854347
(State or other jurisdiction of incorporation or organization)	(Commission File Number)	(I.R.S. Employer Identification No.)
(state or other jurisdiction of incorporation)	(Commission File Number)	(I.R.S. Employer Identification No.)

One Pennsylvania Plaza, Suite 1025

New York, NY

10119

(Address of principal executive offices)

(Zip Code)

New York, NY 10119

(Address of principal executive offices)

Registrant’s telephone number, including area code: (212) 605-0300

~~N/A~~Not applicable

(Former name or former address, if changed since last report.)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

☐	Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

☐	Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

☐	Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

☐	Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

Title of each class		Trading Symbol~~(s)~~		Name of each exchange on which registered
Common Stock, $0.0001 par value per share		LBRX		The Nasdaq Stock Market LLC

Indicate by check mark whether the registrant is an emerging growth company as defined in ~~as defined in~~ Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

Emerging growth company ☒

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

Item 52.0302 ~~Amendments~~Results ~~to Articles~~ of ~~Incorporation~~Operations orand ~~Bylaws;~~Financial ~~Change in Fiscal Year~~Condition.

~~Amendment~~On ~~and~~November 6, ~~Restatement~~2025, ofLB ~~Certificate~~Pharmaceuticals Inc (the “Company”) issued a press release announcing its financial results for the quarter ended September 30, 2025. A copy of ~~Incorporation~~the press release is furnished hereto as Exhibit 99.1.

InThe ~~connection~~information ~~with~~in ~~the~~this ~~closing~~Item of2.02, ~~the~~including ~~initial~~Exhibit ~~public~~99.1 ~~offering~~attached ofhereto, ~~shares~~is ofbeing ~~common~~furnished ~~stock~~and ~~(the~~shall not be deemed “~~IPO~~filed”) for purposes of LBSection 18 ~~Pharmaceuticals~~of ~~Inc~~the Securities Exchange Act of 1934, as amended (the “~~Company~~Exchange Act”) onor ~~September 12,~~otherwise ~~2025,~~subject to the ~~Company~~liabilities ~~filed~~of anthat ~~amended~~section. ~~and~~The ~~restated~~information ~~certificate~~contained ofin ~~incorporation~~this ~~(the~~Item ~~“Restated~~2.02 ~~Certificate”)~~and ~~with~~in the ~~Secretary~~accompanying ofexhibit ~~State~~is ofnot ~~the~~incorporated ~~State~~by ofreference ~~Delaware.~~in ~~The~~any filing of the Company’s ~~board~~under the Securities Act of ~~directors~~1933, as amended (the “~~Board~~Securities Act”), ~~and~~or ~~stockholders~~the ~~previously~~Exchange ~~approved~~Act, whether made before or after the ~~Restated~~date ~~Certificate~~hereof, toregardless beof ~~effective~~any general incorporation language in such filing, except as ofshall ~~immediately~~be ~~prior~~expressly toset ~~the~~forth ~~closing~~by ofspecific ~~the~~reference ~~IPO~~in such filing.

Amendment and Restatement of Bylaws

Effective as of September 12, 2025, the Company adopted amended and restated bylaws (the “Restated Bylaws”) in connection with the closing of the IPO. The Board and stockholders previously approved the Restated Bylaws to be effective immediately prior to the closing of the IPO.

The foregoing descriptions of the Restated Certificate and Restated Bylaws are qualified in their entirety by reference to the full text of the Restated Certificate and Restated Bylaws, which are filed as Exhibits 3.1 and 3.2 hereto, respectively, and are incorporated herein by reference.

Item 9.01

Financial Statements and Exhibits.

(d) Exhibits.

ExhibitNo.		Description
3.1		Amended and Restated Certificate of Incorporation of the Registrant.
99.1		Press Release dated November 6, 2025.
3.2		Amended and Restated Bylaws of the Registrant (incorporated herein by reference to Exhibit 3.4 to the Registrant’s Registration Statement on Form S-1 (File No. 333-289812), filed with the Commission on August 22, 2025).
104		Cover Page Interactive Data File (the cover page XBRL tags are embedded within the Inline XBRL document)
104		Cover Page Interactive Data File (embedded within the Inline XBRL document).

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

LB ~~Pharmaceuticals~~PHARMACEUTICALS ~~Inc~~INC By: /s/ Heather Turner Heather Turner Chief Executive Officer

Dated: ~~September~~November 126, 2025

Filing Compare · LB PHARMACEUTICALS INC